BBOT
HEALTHCAREBridgeBio Oncology Therapeutics Inc Com
$8.33+0.06 (+0.73%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving BBOT Today?
No stock-specific AI insight has been generated for BBOT yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$7.63$14.87
$8.33
Fundamentals
Market Cap$667M
P/E Ratio—
EPS$-4.30
Dividend Yield—
Dividend / Share—
ROE-0.5%
Profit Margin—
Debt / Equity—
Trading
Volume168K
Avg Volume (10D)—
Shares Outstanding80.1M
BBOT News
20 articles- Lilly tumbles on Foundayo’s shaky week; FDA to issue vouchers for psychedelicsBiopharmadive·Apr 24, 2026
- BBOT Presents Preclinical Data Demonstrating pan-KRAS Inhibitor BBO-11818 Has Robust Anti-Tumor Activity in KRAS-Mutant Preclinical Models at the AACR Annual Meeting 2026Yahoo Finance·Apr 22, 2026
- BBOT Announces the Appointment of Pedro J. Beltran, PhD, as Chief Executive Officer, Idan Elmelech as Chief Operating Officer, and Neil Kumar, PhD, as Executive ChairmanYahoo Finance·Apr 22, 2026
- BBOT Presents Preclinical Data Showing RAS:PI3Kα Breaker BBO-10203 Inhibits PI3Kα/AKT Signaling in HER2AMP Models at the AACR Annual Meeting 2026Yahoo Finance·Apr 21, 2026
- BBOT Granted U.S. FDA Fast Track Designation for BBO-11818 for the Treatment of Adult Patients with Advanced KRAS-Mutant Pancreatic Ductal AdenocarcinomaYahoo Finance·Apr 20, 2026
- BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Apr 13, 2026
- BBOT Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026Yahoo Finance·Mar 18, 2026
- This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know?Motley Fool·Mar 16, 2026
- This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover DealMotley Fool·Mar 16, 2026
- Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 LaunchMotley Fool·Mar 16, 2026
- This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last QuarterMotley Fool·Mar 16, 2026
- BridgeBio Oncology (BBOT) Spotlights Next-Gen RAS Pipeline, $425M Cash Runway Into 2028Marketbeat·Mar 13, 2026
- BBOT Announces Publication in Cancer Discovery Highlighting Preclinical Data Demonstrating BBO-11818 is a Potent and Selective panKRAS InhibitorYahoo Finance·Mar 6, 2026
- BBOT Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate ProgressYahoo Finance·Mar 5, 2026
- BridgeBio Oncology Touts “Best in RAS” Pipeline, Highlights BBO-8520 Response and Combo TolerabilityMarketbeat·Feb 26, 2026
- BBOT to Participate in Upcoming Investor Healthcare ConferencesYahoo Finance·Feb 12, 2026
- A Look At BridgeBio Oncology Therapeutics (BBOT) Valuation After Recent Share Price MomentumYahoo Finance·Jan 25, 2026
- BBOT Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated RAS and PI3Kα Pipeline ProgramsYahoo Finance·Jan 7, 2026
- Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million?Motley Fool·Dec 22, 2025
- BBOT to Present at the 44th Annual J.P. Morgan Healthcare ConferenceYahoo Finance·Dec 16, 2025
All 20 articles loaded
Price Data
Open$8.35
Previous Close$8.27
Day High$8.50
Day Low$8.15
52 Week High$14.87
52 Week Low$7.63
52-Week Range
$7.63$14.87
$8.33
Fundamentals
Market Cap$667M
P/E Ratio—
EPS$-4.30
Dividend Yield—
Dividend / Share—
ROE-0.5%
Profit Margin—
Debt / Equity—
Trading
Volume168K
Avg Volume (10D)—
Shares Outstanding80.1M
About BridgeBio Oncology Therapeutics Inc Com
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of small molecule inhibitor for cancer patients. The company is headquartered in South San Francisco, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—